Highlights
- The addition of camrelizumab to gemcitabine and cisplatin (GP) chemotherapy significantly extended the 5-year overall survival (OS) rate to 37.8%, compared to 24.2% with chemotherapy alone.
- Adjusted analysis revealed a 35% reduction in the risk of death (HR, 0.65) for patients receiving the PD-1 inhibitor combination.
- Rapid clearance of plasma Epstein-Barr virus (EBV) DNA emerged as a potent predictor of long-term survival in the immunotherapy cohort.
- CAPTAIN-1st provides the first randomized, double-blind, 5-year evidence confirming the durable benefit of first-line chemo-immunotherapy in recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).
Background
Nasopharyngeal carcinoma (NPC) is a distinct head and neck malignancy with a high prevalence in Southern China, Southeast Asia, and North Africa. The vast majority of cases in these endemic regions are associated with Epstein-Barr virus (EBV) infection. For decades, the standard first-line treatment for recurrent or metastatic NPC (RM-NPC) was gemcitabine plus cisplatin (GP) chemotherapy. While initial response rates were high, long-term survival remained poor, with a 5-year overall survival (OS) rate often hovering below 20%.
The advent of immune checkpoint inhibitors, specifically those targeting the programmed cell death 1 (PD-1) pathway, has revolutionized the treatment landscape. Early-phase trials and subsequent phase 3 studies, such as JUPITER-02 and RATIONALE-309, demonstrated that adding PD-1 inhibitors to GP chemotherapy significantly improved progression-free survival (PFS). However, the ultimate goal of oncology—significant and durable improvement in overall survival at the 5-year landmark—had not been definitively established in a randomized controlled setting until the long-term follow-up of the CAPTAIN-1st trial.
Key Content
The CAPTAIN-1st Trial: Study Design and Baseline Characteristics
The CAPTAIN-1st trial was a multicenter, randomized, double-blind, phase 3 clinical trial conducted across 28 hospitals in China. The study enrolled 263 patients with treatment-naive RM-NPC. Participants were randomized in a 1:1 ratio to receive either camrelizumab (200 mg) or a placebo, combined with gemcitabine (1000 mg/m²) and cisplatin (80 mg/m²). This combination was administered for 4 to 6 cycles, followed by maintenance therapy with either camrelizumab or placebo for up to 2 years or until disease progression or unacceptable toxicity.
At baseline, the groups were well-balanced regarding sex, ECOG performance status, and disease burden. However, a slight age imbalance was noted (mean age 49 years), which was accounted for in the prespecified secondary analysis. The primary endpoint was PFS by an independent review committee, which previously favored the camrelizumab group. The 5-year OS data, recently reported in JAMA Oncology (2026), represents the critical secondary endpoint required to validate the curative potential of this regimen.
Five-Year Overall Survival Outcomes
With a median follow-up exceeding 63 months, the CAPTAIN-1st trial provides the most mature data to date for PD-1 inhibition in RM-NPC. The results are clinically transformative:
- Median Overall Survival: Patients in the camrelizumab group achieved a median OS of 34.5 months (95% CI, 29.4-45.7), whereas the placebo group reached 26.6 months (95% CI, 19.8-33.5).
- Hazard Ratio (HR): The unadjusted HR for death was 0.74 (95% CI, 0.55-0.99). After adjusting for the baseline age imbalance, the HR improved to 0.65 (95% CI, 0.48-0.89; P = .01), indicating a highly significant reduction in the risk of mortality.
- The 5-Year Landmark: The 5-year OS rate was 37.8% for the camrelizumab group vs. 24.2% for the placebo group. This absolute difference of 13.6% underscores the “tail of the curve” effect characteristic of successful immunotherapy, where a subset of patients achieves long-term survival.
Subgroup Consistency and Biomarker Insights
The OS benefit was generally consistent across various subgroups, including those based on PD-L1 expression levels. This suggests that in NPC, PD-L1 may not be the optimal standalone biomarker for patient selection, likely due to the highly inflamed nature of the NPC microenvironment regardless of PD-L1 score.
A standout finding of the CAPTAIN-1st secondary analysis was the role of EBV DNA dynamics. In the camrelizumab arm, patients who achieved rapid clearance of plasma EBV DNA (defined as undetectable levels within the first few cycles of treatment) had a dramatically lower risk of death (HR, 0.32; 95% CI, 0.18-0.58; P < .001). This confirms EBV DNA as a critical liquid biopsy tool for monitoring treatment response and prognosticating long-term outcomes in RM-NPC.
Safety and Maintenance Therapy
Long-term safety data remained consistent with the initial reports. The addition of camrelizumab did not introduce new safety signals during the 5-year follow-up. Immune-related adverse events (irAEs), such as reactive cutaneous capillary endothelial proliferation (RCCEP), were common but generally manageable and did not lead to a significant increase in treatment-related deaths. The 2-year cap on maintenance therapy appeared sufficient to induce durable responses in the long-term survivor subgroup.
Expert Commentary
The CAPTAIN-1st 5-year analysis is a landmark achievement in the field of nasopharyngeal carcinoma. While earlier reports from trials like JUPITER-02 (toripalimab) and RATIONALE-309 (tislelizumab) set the stage for chemo-immunotherapy, the maturity of the CAPTAIN-1st data provides the definitive evidence clinicians have sought.
A key point of discussion is the HR adjustment for age. While the raw P-value was 0.047, the age-adjusted HR of 0.65 provides a more robust reflection of the drug’s efficacy, especially given that younger age is typically a favorable prognostic factor in NPC. The 13.6% absolute improvement in 5-year OS is substantial, effectively shifting RM-NPC from a disease with a very bleak 5-year outlook to one where nearly 40% of patients can survive past the five-year mark when treated with frontline immunotherapy.
The findings regarding EBV DNA clearance are particularly salient. For clinicians, this suggests that monitoring EBV DNA levels isn’t just a measure of tumor burden, but a tool for identifying patients who are likely to become the “long-term survivors.” Future trials may investigate whether therapy can be de-escalated in rapid clearers or intensified in those with persistent DNA.
One limitation of the study is its geographic focus on China. While this is appropriate given the endemic nature of the disease, further real-world evidence in non-endemic populations (e.g., EBV-negative NPC) would be beneficial. Additionally, the role of subsequent therapies after progression on first-line camrelizumab remains a topic of active investigation, as it may influence the final OS outcomes.
Conclusion
The 5-year secondary analysis of the CAPTAIN-1st trial cements the combination of camrelizumab and GP chemotherapy as the foundational first-line treatment for RM-NPC. The statistically significant and clinically meaningful improvement in overall survival—the gold standard in oncology—provides high-level evidence that justifies the widespread adoption of this regimen. As we move forward, the integration of liquid biopsy (EBV DNA) into clinical decision-making and the exploration of next-generation immunotherapies will likely continue to improve the outlook for patients with this challenging disease.
References
- Huang Y, et al. Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. JAMA oncology. 2026-Mar-01;12(3):295-302. PMID: 41609753.
- Yang Y, et al. Camrelizumab plus gemcitabine and cisplatin versus placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2021;22(8):1162-1174. PMID: 34175080.
- Mai HQ, et al. Toripalimab plus chemotherapy as second-line treatment or later for patients with metastatic nasopharyngeal carcinoma (JUPITER-02): a randomised, double-blind, phase 3 trial. Nat Med. 2021;27(9):1536-1543. PMID: 34385734.